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ABSTRACT
Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual 
myeloma cells surviving even in the patients who achieve complete clinical response to treatment. In recent years there is a huge improvement in 
treatment of patients with multiple myeloma. The milestones of these improvement are: autologous transplantation and high-dose melphalan, 
imunomodulating drugs (thalidomide, lenalidomide), proteosom inhibitors (bortesomib, carfilzomib). The most significant improvement in overall 
survival has been achieved in the patients younger than 65 years. So, the major challenge for hematologist is to translate this improvement in the 
elderly patients with multiple myeloma. Today, physicians are able to offer wider variety of treatment options for elderly patients with multiple 
myeloma. Therapeutic options should be tailored and personalized according to patient’s characteristics by balancing efficacy and toxicity of each 
drug which is especially important for elderly patients. In the mode of sequencing treatment for elderly patients with multiple myeloma, our goal is 
to achieve and maintain maximal response while limiting treatment -related toxicities as much as possible. Second-generation novel agent, such as 
carfilzomib, pomalidomide, elotuzumab, bendamustine are currently being evaluated as an option to improve treatment outcome in elderly patients.
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Myeloma multiplex is a malignant disorder first recognized 
in the 19th century and at that time point was described as 
“mollities ossium” accompanied by the presence of Bence Jones 
protein in urine. At that time there was no effective treatment 
and median overall survival was only short: a few months. 
Over the time, especially over the past decade, many advances 
in myeloma treatment have been made and improvement of 
the median overall survival have been achieved. But, myeloma 
multiplex is still considered incurable disease (1, 2).
Myeloma multiplex is a malignant disorder that arises from 
the malignant proliferation of plasma cell and is characterized 
by the presence of at least 10% clonal bone marrow plasma cells 
and serum and/or urinary monoclonal protein. Myeloma mul-
tiplex accounts for 1% of all types of cancers and is the second 
most common hematologic neoplasm, approximately 13% for 
all hematologic malignances. Myeloma multiplex is considered 
as a disease of elderly reflected by the average age at diagnosis 70 
years, with 37% of patients younger than 65 years, 26% aged 65 
to 74 years, and 37% older than 75years (3, 4, 5).
Patient with myeloma multiplex could be diagnosed as symp-
tomatic or asymptomatic disease. Patients with a symptomatic 
disease should be treated immediately, and the mainstay of 
asymptomatic disease is still an observation. Symptomatic 
disease could be defined with so called CRAB features: C- hy-
percalcemia (>11.5mg/dl (2.65mmol/l); R-renal failure (serum 
creatinin >mg/dl; 1.73mmol/l); A-anemia (hemoglobin <10g/
dl; 12.5 mmol/l) or 2 g/dl; 1.25mmol/l below the lower limit 
of normal; and B-bone disease (lytic lesions, severe osteopenia, 
or pathologic fractures). Patients are stratified into three risk 
groups according to the International Staging system (ISS). This 
system defines three risk groups based on serum beta 2 micro 
globulin and albumin levels at diagnosis. High-risk disease and 
poor prognosis are defined with the presence of high levels of 
serum beta2 micro globulin (stage III) (6).
Nowadays, chromosomal abnormalities t(4;14), t(14;16) and 
t(14;20) chomosome 1 abnormalities and del17 detected by fluo-
rescent in situ hybridization (FISH) are associated with poor 
prognosis. Hiperdiplpdy, t (11;14), t (6,14), are associated with 
good prognosis and can be considered “standard risk” (7, 8, 9).
Initial therapy for multiple myeloma depends to a certain ex-
tent on patients characteristics such as: eligibility for autologous 
stem cell transplantation per se; age and co-morbidities. The role 
of induction therapy is to induce remission, but patient’s charac-
teristics have a significant role in the initial treatment approach. 
Goals of treatment are: to eradicate the tumor clone, including 
cancer stem cell, to search for an appropriate balance between 
efficacy and toxicity with three different but complementary 
aims: quality of life, survival prolongation and eventually the 
dream of cure. This can be achieved if we use appropriate tools 
to evaluate treatment efficacy. Achieving the lowest level of 
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minimal residual disease can be an important goal of therapy, 
a step in the path to cure (9, 10).
Today, treatment goals in myeloma patients are shifting and 
the goal of therapy in elderly patients is to achieve and maintain 
maximal response. Many believe that multiple myeloma can 
be converted into a chronic disease and that a functional cure 
maybe a realistic goal. Attainment of complete remission at any 
time point during treatment is associated with improvement 
outcome; so it is likely to be established as a goal of therapy (11, 
12, 13, 14). The increasing number of treatment possibilities 
as an optimal therapeutic strategy improve patient outcome. 
Physicians have the opportunity to choose the best treatment 
regimen according to patient characteristics, while limiting 
treatment – related toxicities as much as possible. In elderly 
patients optimal treatment should be always balance efficacy 
and toxicity (2, 15, 16).
Initial therapy for multiple myeloma depends on eligibil-
ity for high-dose therapy and autologous stem cell transplant 
(HDT-ASCT). (11,17) In many European countries, elderly 
patients (older than 65) are generally considered ineligible for 
autologous stem cell transplantation (ASCT) ( 18). In past times 
in practice, patients were stratified to those who are transplant 
eligible and consolidated with high-dose melphalan/SCT and 
those who were transplant ineligible and received oral melpha-
lan with prednisolone (MP). This stratification has been made 
in the era of conventional therapy where response rates to the 
induction therapy were poor and the goal was achievement of 
partial response and prevention of organ damage. So, in con-
trast, today we considered that biological age and chronological 
age do not always correspond, and a greater emphasis should be 
placed on the former rather than the latter (19). CR is a good 
surrogate end point for survival in transplant-ineligible patients 
and novel drugs have been incorporated into the treatment of 
non-transplant candidates (20). Patients are generally consid-
ered eligible for ASCT if they have good performance status, 
no-comorbidities, and normal cardiac, pulmonary, liver and 
renal function. Patients older than 75 years or vulnerable ones 
are more susceptible to adverse events and in this setting we 
are looking for less toxic regimens and appropriate dose reduc-
tions should be adopted (9, 10, 21). Even, ASCT with a reduced 
melpahlan conditioning dose is well tolerated by the selected 
population of patients up to the age of 75 in good clinical con-
ditions. Until novel agents were introduced, for more than 40 
years the combination of melpahalan and prednisone (MP) was 
considered the standard approach for transplant –ineligible 
patients, with PFS of approximately 18 months and 2-3 years 
(at best) overall survival in the population treated with MP. 
A meta-analysis including 27 randomized studies compared 
MP with other chemotherapy-containing regimens (22). The 
introduction of novel agents has challenged this combination 
and new and more effective combination is available.
Six randomized phase III studies have shown that the com-
bination melphalan-prednisone-thalidomide (MPT) is superior 
to MP in terms of response and progression-free survival, but it 
was translated into improved survival in the 2 IFM studies (23-
28). An efficacy meta-analysis of the six MPT trials including 
1685 patients was conducted and has showed that the addition 
of thalidomide to MP significantly prolonged both PFS and 
extended OS by 20%–39 months compared to MP- 33 months 
(29). The meta–analysis further confirmed the progression-free 
survival advantage achieved with MPT. So, MPT is therefore re-
garded as a new standard of care in transplant ineligible patients.
For selected elderly patients, particularly for standard risk 
patients with favorable FISH, CTD is a feasible approach. A 
phase III assessed the role of thalidomide in combination with 
different alkylating agent and steroid than those commonly 
used, respectively cyclophosphamide and dexamethasone with 
an attenuated schedule (CTDa). Despite a deeper response, no 
differences were noted in median PFS and OS between patients 
treated with CTDa and MP (30).
Lenalidomide is an immunomodulatory drug with higher 
potency than its analogue thalidomide and without sedative or 
neurotoxic adverse effects. Lenalidomide showed to be safe and 
effective in relapsed/refractory multiple myeloma patients, as 
well as in newly diagnosed multiple myeloma patients.
The phase III trial RD (lenalidomide plus high-dose dexa-
methason) versus Rd (lenalidomide plus low-dose dexametha-
son) included newly diagnosed multiple myeloma patients both 
eligible and ineligible for autologus stem cell transplantation. 
Rd seems preferable for elderly patients because has significantly 
longer 1-year overall survival, particularly evident in patients 
older than 65 years of age and can be considered a valid thera-
peutic option for elderly newly diagnosed myeloma patients. RD 
remains a good option for patients with renal failure, hypercal-
cemia, pain or spinal cord compression because more adverse 
events occurred when RD was given compared with Rd (31).
The role of lenalidomide was assessed in a recent phase III 
study that compared melphalan-prednisone-lenalidomide fol-
lowed by lenalidomide maintenance (MPR-R), with MPR and 
MP. MPR-R significantly improved median progression-free 
survival compared with MPR and MP (31 months versus 14 
months vs. 13 months; p<0.001), which means that MPR-R 
reduced the risk of progression by 51% and 60% compared with 
MPR and MP. Lenalidomide maintenance was well tolerated 
with few reported incidence of grade ¾ adverse events and 
second cancer. However the benefit associated with MPR-R 
outweigh the increased risk of second primary malignancies 
(32, 33).
VISTA study compared MP versus VMP and proved that 
addition of bortezomib to MP is rational, because responses, 
time to progression and survival were significantly higher with 
VMP (34, 35).
In the Spanish PETHEMA trial a cohort of 260 patients 
older than 65, transplant ineligible, were randomized to receive 
induction treatment with 6 cycles of bortezomib-thalidomeide-
prednisone VTP, or VMP considered as more gentle approach 
where melphalan is used instead of thalidomide(36). Both 
regimens led to high ORR rate (81%and 80%), but there were 
more adverse events among patients with VDT. VMP with 
once-weekly schedule of botezomib should be preferred to VTP 
as induction for elderly multiple myeloma patients. One-weekly 
bortezomib was scheduled instead of standard twice-weekly 
administration to reduce adverse events, especially neuropathy 
associated with bortezomib administration.
The combination of bortezomib-lenalidomide-dexametha-
sone (VRD) was evaluated in both young and elderly patients 
with multiple myeloma.
The addition of thalidomide to the new treatment standard 
with VMP followed by bortezomib-thalidomide maintenance 
is valid alternative with 3-years overall survival 565 with VMP-
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VT compared with 41% with VMP. VMP-VT with once weekly 
bortezomib seems to be a valid alternative for elderly patients 
particularly those younger than 75 years, where there is the same 
efficacy, but without additional toxicity, particular peripheral 
neuropathy (37).
A sequential approach consisting of an induction regimen 
associated with a high rate of complete response, followed by 
consolidation, maintenance therapy, induce a profound cytore-
duction and delays relapse, thus improving survival as a therapy 
approach that minimized toxicity maximized quality of life 
and emphasized patient’s preference. This choice of treatment 
strategy improve outcome and prevent the occurrence of relapse 
with a continuous treatment keeping residual disease under 
control. The international MM015 phase III study assessed 
the role of lenalidomide given in maintenance. Having this in 
mind MPR followed by lenalidomide maintenance emerges as 
a new standard treatment option for elderly multiple myeloma 
patients. Another treatment option for elderly patients with 
impressive result is more intensive regimen VMPT followed 
by VT maintenance. Bortezomib showed same efficacy with 
decreased toxicity administrated in a new schedule from twice 
to once weekly (38).
As we already emphasized, the choice among these regimens 
should be based on the patient’s characteristics. For elderly 
patients with renal impairment bortezomib or thalidomide 
containing regiment is considered the best treatment option, 
because lenalidomide is excreted by the kidneys. In such a case 
dose of lenalidomide should be reduced according to creatinin 
clearance. Despite that, for patients with peripheral neuropathy 
lenalidomide is considered as the best treatment option because 
of the reduced neurological toxicity. In elderly patients there is 
an increased risk of treatment-related adverse events in response 
to novel agent-containing regimens. Clinicians should be aware 
and proposed guidelines for dose reduction of novel agents and 
protocol modification in elderly should be followed in clinical 
practice for elderly patients with multiple myeloma to optimize 
outcome. So, there is an attempt to personalize the therapy in 
multiple myeloma according to patient age and vulnerability 
proposed by European Myeloma Network (EMN) (16, 17, 39).
Multiple myeloma is still an incurable disease with pat-
tern of regression and remission followed by multiple relapses 
raising from the residual myeloma cells surviving even in the 
patients who achieve complete clinical response to treatment. 
New anti-myeloma drugs change treatment paradigm providing 
both tumor reduction and tumor suppression. There is so much 
progress, but still many unsolved questions. Today, physicians 
are able to offer wider variety of treatment options for both 
young and elderly patients with multiple myeloma. Therapeu-
tic options should be tailored and personalized according to 
patient’s characteristics by balancing efficacy and toxicity of 
each drug which is especially important for elderly patients. 
In the mode of sequencing treatment for elderly patients with 
multiple myeloma, our goal is to achieve and maintain maximal 
response while limiting treatment -related toxicities as much as 
possible. Second-generation novel agent, such as carfilzomib, 
pomalidomide, elotuzumab, bendamustine are currently be-
ing evaluated as an option to improve treatment outcome in 
elderly pateints (2).
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